Among the pharma company updates, Teva’s new CEO Richard Francis is confident about the company’s growth, while Y-mAbs President Thomas Gad offered more insights into the company’s 35% workforce reduction and pipeline restructuring.

The company was seeking approval of omburtamab to treat a rare form of nerve cancer in pediatric patients. The FDA’s decision follows a unanimous vote in October against the drug to treat neuroblastoma due to insufficient evidence that it improves overall survival.